Belite Bio (BLTE) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Belite Bio, Inc - American Depositary Shares (BLTE)
Company Research
Source: Yahoo! Finance
Image source: The Motley Fool. Date Monday, March 2, 2026 at 4:30 p.m. ET Call participants Chief Executive Officer — Hao-Yuan Chuang Chief Financial Officer — Tom Lin Chief Scientific Officer — Nathan Mata Chief Medical Officer — Hendrik Scholl Need a quote from a Motley Fool analyst? Email pr@fool.com Full Conference Call Transcript Hao-Yuan Chuang: Thank you for joining today's call to discuss our fourth quarter and full year 2025 financial results. 2025 was a year of significant progress for us as we achieved several key milestones. We look forward to a truly transformative year in 2026, as we position Tadaraben to potentially become the first ever approved therapy for people living with Stargardt disease, a devastating eye disease that usually begins in childhood or young adulthood and leads to progressive vision loss and then legal blindness in almost all cases. Today, I will provide a recap of our 2025 achievements, key milestones for 2026, and financial re
Show less
Read more
Impact Snapshot
Event Time:
BLTE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLTE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLTE alerts
High impacting Belite Bio, Inc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BLTE
News
- Belite Bio price target raised to $266 from $200 at Cantor Fitzgerald [Yahoo! Finance]Yahoo! Finance
- Belite Bio (BLTE) was given a new $217.00 price target by Needham & Company LLC.MarketBeat
- Belite Bio (BLTE) had its price target raised by HC Wainwright from $185.00 to $200.00. They now have a "buy" rating on the stock.MarketBeat
- Belite Bio (BLTE) had its "buy" rating reaffirmed by Benchmark Co..MarketBeat
- Belite Bio (BLTE) had its price target raised by Morgan Stanley from $191.00 to $201.00. They now have an "overweight" rating on the stock.MarketBeat
BLTE
Earnings
- 3/2/26 - Beat
BLTE
Sec Filings
- 3/2/26 - Form 6-K
- 2/17/26 - Form SCHEDULE
- 1/30/26 - Form S-8
- BLTE's page on the SEC website